FDMT
4D Molecular Therapeutics Inc

1,241
Mkt Cap
$619.34M
Volume
486,486.00
52W High
$12.34
52W Low
$2.24
PE Ratio
-2.77
FDMT Fundamentals
Price
$10.89
Prev Close
$10.84
Open
$10.86
50D MA
$9.77
Beta
1.28
Avg. Volume
873,657.91
EPS (Annual)
-$2.98
P/B
1.38
Rev/Employee
$163.00
Loading...
Loading...
News
all
press releases
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are covering the firm, MarketBeat...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,314.65 in Stock
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the company's stock in a transaction on Monday, November 17th. The shares were sold at an...
MarketBeat·4d ago
News Placeholder
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2% - What's Next?
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Up 6.2% - Time to Buy...
MarketBeat·4d ago
News Placeholder
4DMT Appoints Kristian Humer As CFO
(RTTNews) - 4D Molecular Therapeutics, Inc. (FDMT), a biotechnology company, Monday announced that it has appointed Kristian Humer as its new chief financial officer...
Nasdaq News: Markets·8d ago
News Placeholder
4D Molecular Therapeutics (NASDAQ:FDMT) Upgraded at Wall Street Zen
Wall Street Zen upgraded 4D Molecular Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·9d ago
News Placeholder
HC Wainwright Has Optimistic Outlook of FDMT FY2026 Earnings
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities researchers at HC Wainwright raised their FY2026 earnings estimates for shares of 4D Molecular Therapeutics in a report issued...
MarketBeat·9d ago
News Placeholder
FY2025 Earnings Forecast for FDMT Issued By Chardan Capital
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Research analysts at Chardan Capital lifted their FY2025 earnings per share estimates for 4D Molecular Therapeutics in a research note...
MarketBeat·10d ago
News Placeholder
Brokers Offer Predictions for FDMT Q1 Earnings
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of 4D Molecular Therapeutics in...
MarketBeat·10d ago
News Placeholder
Cantor Fitzgerald Issues Negative Forecast for FDMT Earnings
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of 4D Molecular Therapeutics...
MarketBeat·11d ago
News Placeholder
Leerink Partnrs Issues Pessimistic Outlook for FDMT Earnings
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Leerink Partnrs decreased their FY2025 earnings estimates for shares of 4D Molecular Therapeutics in a report issued on Monday, November...
MarketBeat·11d ago

Latest FDMT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.